Close Menu

NEW YORK (GenomeWeb) – Exosome Diagnostics announced last week the launch of a clinical commercialization program to help researchers bring exosome-based biosignature assays to the clinical lab.

Through the free program, called "Academic Bench to Clinical Diagnostics," or A to D, Exosome will help researchers port existing assays to the firm's patented exosome isolation and nucleic acid extraction system to increase sensitivity, and then guide the test through the regulatory and reimbursement process.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.

The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.

Researchers have sequenced the genome of "the Methuselah of freshwater fish."

In Genome Biology this week: difference in methylation in neurons from Parkinson's disease patients, differential expression analysis by barcoded sequencing approach, and more.